Symphony Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/auaxdg0ar46vl2lr6ym7fa03.pdf

Key Takeaways


Q3 Standalone: The Quarter That Wasn’t

Nrupesh Shah: “There has been temporary calibration in EBITDA and business PAT, mainly because low margin models have been billed in December ’24 quarter, and in addition to that, there has been water heater launch expenses and also forex loss of ₹3.8 crores on a stand-alone basis.”

The Pathways Credit Event

Achal Bakeri: “there’s clearly a lapse of judgment… sometimes in the lure of sales or with the fear of not losing sales, we sometimes tend to overlook some signals which would have been otherwise very evident.”

Consolidated Group: The Structural Story Intact

Achal Bakeri: “The issue now in Australia is nothing other than top line. As soon as the top line, if we are able to crank up the top line, all the numbers will immediately fall into place. Exactly what happened in GSK China.”

Product Cycle: 17 New Coolers and a Water Heater Bet


Australia: The Pivot from Manufacturing to Selling


Competitive Position and Adjacent Opportunities

Achal Bakeri: “We will not really just source a product which has not been developed by us and where we see no product differentiation. And where the same product would be hocked to different brand brands is not something — it’s not a direction that we will go into.”

Guidance & Commitments

CommitmentSpecificsTimeline
Q4 performanceRobust positive demand and sentiment across trade channel and geographies; record ₹150 cr unbilled advances to convertMarch 2025 quarter
Australia manufacturing closureFactory fully wound down, lease expiresBy June 2025
Australia top-line rampNew product portfolio (ACs, heaters, purifiers) in place; scaling-up underwayFruits expected “down the line”
GSK China loan repaymentClear visibility and path for repayment of remaining ₹50 cr“In time to come”
Water heater scale-upInitial focus on modern trade, e-commerce, large regional chainsComing 12 months are the key demonstration period
Credit risk mitigationCredit insurance taken for entire modern trade; limits rationalised; in-depth evaluation implementedEffective immediately
Legal recovery from PathwaysCriminal proceedings, property rights created, bail cancellation filed, cheque-dishonour complaint filedOngoing

Key Metrics

MetricQ3 FY25
Standalone revenue₹814 cr (9M), +49% YoY; Q3 muted
Consolidated revenue₹1,088 cr (9M), +32% YoY; Q3 ₹242 cr, flattish
Standalone EBITDA₹188 cr (9M), +91% YoY; Q3 ₹34 cr before specific expenses
Standalone EBITDA margin18.8% (Q3), impacted by low-margin model mix and specific expenses
Consolidated EBITDA₹211 cr (9M); margin 19.4%, +570 bps YoY; Q3 margin 14.7%
Consolidated gross margin50.50% (9M), +260 bps YoY
Standalone PAT₹132 cr (9M); Q3 negative ₹4 cr after ₹53 cr specific expenses
Consolidated PAT₹134 cr (9M), +34% YoY; Q3 negative ₹10 cr
Standalone Return on Net Worth24% (trailing 12 months)
Consolidated ROCE90% on core capital employed (trailing 12 months)
Consolidated Return on Net Worth26% vs 15% YoY
Treasury₹488 cr as of 31st December
Unbilled advances₹150 cr record as of 31st December, for 17 new models
Total payout₹124 cr (9M), 92% of consolidated profit; interim dividend ₹2 per share
Doubtful debt provision₹46 cr provided in Q3 for Pathways Retail (total provision ₹58 cr)
Forex loss₹3.8 cr standalone, ₹9 cr consolidated (notional, mark-to-market)
Water heater launch expenses₹3.6 cr in Q3
Subsidiaries combined revenue₹327 cr (9M), +10% YoY; Q3 ₹88 cr
Subsidiaries combined EBITDA₹24 cr (9M) vs ₹15 cr; Q3 almost zero
GSK China revenue₹75 cr (9M) vs ₹33 cr YoY
GSK China PAT₹10 cr (9M) vs ₹1 cr YoY
Climate Technologies CODBReduced to A$7.5 mn from A$15 mn at acquisition
Peak US sales (historical)\$23 mn annually, currently low; tariffs have no direct impact